Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 26.
doi: 10.1007/s10384-025-01265-5. Online ahead of print.

Short-term outcomes of the PreserFlo MicroShunt in Japanese patients with exfoliation glaucoma: a comparison with primary open-angle glaucoma using propensity score matching

Teruki Yamae  1 , Rei Sakata  2   3 , Haruyuki Suzuki  1 , Yurika Aoyama  1 , Hotaka Nemoto  1 , Hitomi Saito  1   4 , Megumi Honjo  1   4 , Shiroaki Shirato  4 , Makoto Aihara  1   4
Affiliations

Short-term outcomes of the PreserFlo MicroShunt in Japanese patients with exfoliation glaucoma: a comparison with primary open-angle glaucoma using propensity score matching

Teruki Yamae et al. Jpn J Ophthalmol. .

Abstract

Purpose: This study evaluated the efficacy and safety of initially implanted PreserFlo MicroShunt (PMS) in Japanese patients with exfoliation glaucoma (XFG). Using propensity score matching, intraocular pressure (IOP) control rates were compared between patients with XFG and primary open-angle glaucoma (POAG).

Study design: Retrospective observational study.

Methods: This study reviewed 31 eyes of 31 patients with XFG who underwent initial PMS implantation with mitomycin C. IOP, medication scores, and corneal endothelial cell density (CECD) were assessed preoperatively and at up to 6 months postoperatively. Kaplan-Meier analysis was used to estimate the 6-month survival rate, defined as an IOP reduction of > 20% from baseline and an IOP < 15 mmHg. The incidences of needling, reoperation, and complications were also assessed. IOP control was compared between XFG and propensity-score-matched POAG patients using the log-rank test.

Results: At 6 months, the mean IOP had decreased significantly, from 22.3 ± 6.6 to 14.7 ± 6.6 mmHg, and the medication score had declined from 4.5 to 1.4. CECD decreased from 2127 to 1902 cells/mm2, although this was not statistically significant. The complete success rate (without any glaucoma medications or intervention) was 48%. Postoperative complications included anterior chamber hemorrhage and choroidal detachment. Needling was performed in nine eyes (29.0%), and additional surgery was performed in five eyes (16.1%). Compared to POAG patients (11.9 mmHg), XFG patients had higher postoperative IOP (14.8 mmHg) and higher medication scores (0.5 vs 1.4, p = 0.04) and a lower success rate (62.2% vs 41.7%).

Conclusions: PMS in Japanese patients with XFG resulted in a significant IOP reduction over 6 months, with a relatively favorable safety profile. However, its efficacy was slightly inferior to that in POAG, implying potential differences in PMS responsiveness between glaucoma subtypes.

Keywords: Exfoliation glaucoma; Intraocular pressure; PreserFlo MicroShunt; Primary open-angle glaucoma; Propensity score matching.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: T. Yamae, None; R. Sakata, Royalties or licenses (Santen), Consulting fees (Santen), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Otsuka, Kowa), Participation on a Data Safety Monitoring Board or Advisory Board (Santen), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Santen, Kowa); H. Suzuki, None; Y. Aoyama, None; H. Nemoto, Grant (Novartis Pharma Grants for Basic Research 2022), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Kowa, TOPCON); H. Saito, Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Otsuka, Kowa, ZEISS, TOPCON, AbbVie, Novartis, Viatris, Rhoto, Sandoz); M. Honjo, Grants or contracts from any entity (Santen, Alcon), Consulting fees (Santen), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Otsuka, Kowa, Novartis, Senju), Participation on a Data Safety Monitoring Board or Advisory Board (Santen), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Santen, Kowa); S. Shirato, Consulting fees (Santen, Otsuka, Senju, Kowa); M. Aihara, Grants or contracts from any entity (Santen, Alcon, Pfizer, Otsuka, Johnson & Johnson, TOMEY, CREWT Medical Systems, Senju, Novartis, Kowa, Wakamoto, Glaukos, Ono, Sato), Consulting fees (Santen, Alcon, Kowa, Wakamoto, Glaukos, Astellas, Senju, Pfizer, Otsuka, HOYA, IRIDEX Medical Systems), Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events (Santen, Senju, Alcon, Novartis, Pfizer, Kowa, Otsuka, Johnson & Johnson, HOYA, Glaukos, TOMEY, IRIDEX, CREWT Medical Systems, CANON, ZEISS, Sato, Wakamoto, Astellas), Participation on a Data Safety Monitoring Board or Advisory Board (Santen, Senju, HOYA, Kowa), Receipt of equipment, materials, drugs, medical writing, gifts or other services (Kowa, Santen).

Similar articles

See all similar articles

References

    1. Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023; 67:189–254. - PubMed
    1. Ozaki M. Mechanisms of glaucoma in exfoliation syndrome. J Glaucoma. 2018;27(Suppl 1):S83–6. - PubMed
    1. Heijl A, Bengtsson B, Hyman L, Leske MC. Natural history of open-angle glaucoma. Ophthalmology. 2009;116:2271–6. - PubMed
    1. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:182–5. - PubMed
    1. Kivelä TT. Histopathology of exfoliation syndrome. J Glaucoma. 2018;27(Suppl 1):S38-43. - PubMed

LinkOut - more resources